NYSEAMERICAN:PFNX - Pfenex Stock Price, Forecast & News

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

Pfenex Inc (NYSEAMERICAN:PFNX) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported $0.09 EPS for the quarter, hitting the Zacks' consensus estimate of $0.09. The biotechnology company earned $15.25 million during the quarter, compared to the consensus estimate of $14.80 million. View Pfenex's Earnings History.

Pfenex is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Pfenex.

4 Wall Street analysts have issued 12 month price targets for Pfenex's shares. Their forecasts range from $17.00 to $20.00. On average, they expect Pfenex's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 57.7% from the stock's current price. View Analyst Price Targets for Pfenex.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

News stories about PFNX stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pfenex earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Pfenex.

Some companies that are related to Pfenex include Vir Biotechnology (VIR), Clinuvel Pharmaceuticals (CUV), Polynovo (PNV), Concordia International (CXR), Mesoblast (MSB), Immutep (IMM), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Starpharma (SPL), Oxford BioMedica (OXB), Silence Therapeutics (SLN), Biotest (BIO), Bellus Health (BLU), TELIX Pharmaceutical (TLX) and Neptune Wellness Solutions (NEPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Ocular Therapeutix (OCUL), Fate Therapeutics (FATE), Opko Health (OPK), Relypsa (RLYP), Spectrum Pharmaceuticals (SPPI), TherapeuticsMD (TXMD), Verastem (VSTM), Alder Biopharmaceuticals (ALDR), Coherus Biosciences (CHRS) and Dicerna Pharmaceuticals (DRNA).

Pfenex's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.74%), Millennium Management LLC (0.82%), Squarepoint Ops LLC (0.55%), Russell Investments Group Ltd. (0.48%), Commonwealth Equity Services LLC (0.25%) and Point72 Asset Management L.P. (0.24%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell. View Institutional Ownership Trends for Pfenex.

PFNX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Strs Ohio, Man Group plc, Zurcher Kantonalbank Zurich Cantonalbank, Commonwealth Equity Services LLC and Barclays PLC. View Insider Buying and Selling for Pfenex.

PFNX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Point72 Asset Management L.P., State Street Corp, Delta Investment Management LLC, Metropolitan Life Insurance Co NY, California Public Employees Retirement System and California State Teachers Retirement System. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PFNX stock can currently be purchased for approximately $11.73.

Pfenex has a market capitalization of $371.56 million. Pfenex employs 71 workers across the globe.View Additional Information About Pfenex.

The official website for Pfenex is http://www.pfenex.com/.

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.